Dr. Abha Kumari
Radiation Oncology
Oncology
HCG EKO Cancer Centre, Kolkata - Kolkata, India
Qualification
MBBS , DNB RadiotherapyLanguages
English Hindi BengaliWork Experience
7+ YearsResearch Experience
• Rita RSingh U
Trivedi V
Chauhan R
Kumari A (2017) Determinants of Survival of Cervical Cancer: A Hospital Based Study. Gynecol Obstet 7: 437. doi:10.4172/2161-0932.1000437.
• Chatterjee S
Chakraborty S; HYPORT Adjuvant Author Group.
• Hypo fractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)-study protocol for a multicenter
randomized phase III trial. Trials. 2020;21(1):819. Published 2020 Sep 30. doi:10.1186/s13063-020-04751-y
• S. Bhusal
S. Chatterjee
S. Chakraborty
A. Kumari
S. Bachianathan
A. Mahato
P. Lal
S. Gupta
P. Solomon
K.M. Das
S. Mandal. PO-1797: Dosimetric analysis of simultaneous integrated boost in the HYPORT Adjuvant Trial (NCT03788213). DOI:10.1016/S0167-8140(21)01815-6. ESTRO 2020 abstract
• Ritesh santosham
Sanjoy Chatterjee
Santam Chakraborty
Avipsa Das
Abha Kumari Hypo fractionated Radiotherapy with SIB in Advanced Incurable Breast Cancer -HYPORT B study (NCT03669497). DOI:10.13140/RG.2.2.36479.64160
ESTRO 2020 abstract.
Awards & Achivements
• Clinical Research Co-investigator in National cancer registry program (NCRP) in Mahavir Cancer SansthanPatna
• Principal investigator in Quality of life and employment status in head and neck cancer patients from rural area
treated at a tertiary cancer center in tier II city of India: A Prospective cross-sectional study
• Co-investigator in a Intensifying radiation treatment in advanced/ poor prognosis laryngeal
hypopharyngeal (LH) and oropharyngeal cancers (OPC) using PET –CT based dose escalation strategies. (INTELHOPE)
• Co-investigator in HYPOfractionated Radiation Therapy comparing a standard radiotherapy schedule (over three weeks) with a novel one-week schedule in Adjuvant breast cancer: An open label randomized controlled study (HYPORT- Adjuvant)
• Co-Investigator in Hypofractionated Radiotherapy schedule of 26 Gy in 5 fractions with simultaneous integrated boost (6 Gy) in advanced incurable breast cancer: A prospective Phase I/II study. Co-Investigator in a prospective
multicenter
randomized
double blind
parallel group study to compare the efficacy and safety of biosimilar cetuximab versus innovator cetuximab in combination with platinum-based chemotherapy in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (ALK18/ENZ124-CET1)
• Co-investigator in a phase III
double-blind
placebo-controlled
randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumors (ADD-Aspirin
breast cancer cohort)
• Co-investigator in a Phase III
Multicenter
Randomised
Double-Blind
Placebo-Controlled Study of Atezolizumab (Anti−PD-L1 Antibody) in Combination with Paclitaxel Compared with Placebo with Paclitaxel for Patients with Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer (MO39196)
• Co-investigator in a Phase II
multicenter
open-label
two-cohort
non-comparative study to assess the efficacy and safety.
Memberships
• Indian Society of Radiation Oncology (ISRO)• Federation of Asian Biotech Associations (FABA)
• Life Member of the Society for Applied Biotechnology
• Life Member of The Biotech Research Society India
• Member of TMS
USA
• Life Member of IIM
India
• Life Member of IME
India
Area of Interest
• Experienced in administering high-end radiotherapy techniques like 3DCRTIMRT
VMAT
respiratory gating therapy
IGRT
SRS
SRT
brachytherapy
etc.
• Extensive experience in research in the field of head and neck cancer and breast cancer